|
Adult participants (aged 18 - 85 years inclusive) |
|
|
|
|
Diagnosed with Parkinson's disease according to the UK Brain Bank Criteria |
|
|
|
|
Demonstrates a positive response to oral anti-Parkinsonian medications (i.e. dopamine replacement therapies) and treated with these medications for minimum of three years prior to the screening visit |
|
|
|
|
Report limitation to activities of daily living (e.g., writing, walking, bathing, dressing, eating, toileting, etc.) |
|
|
|
|
Able and willing to consent to participate in the study |
|
|
|
|
Willing and able to comply with study requirements |
|
|
|
|
Anticipate being able to remain on a stable regimen of medications used for the management of PD motor and non-motor symptoms and not to introduce new medications used to treat symptoms associated with PD during the trial |
|
|
|
|
Fully vaccinated from COVID-19 (at least 2 weeks from their final dose) with one of the current World Health Organization evaluated vaccines, prior to Screen |
|
|
|
|
Have at minimum a moderate burden of non-motor symptoms associated with Parkinson's disease |
|
|
|
|
Have a study partner (defined as someone who sees the participant for more than one hour a day, 3 times per week) that is willing to consent and participate in the trial |
|
|
|
|
Have capabilities to use and access smartphones and or tablets for the collection of some study data |
|
|
|
|
Must be willing to answer questions related to sexual interest, arousal, and performance in an interview with study staff |
|
|
|
|
Participant anticipates being unable to attend all visits and complete all study activities
|
|
|
|
|
Women of child-bearing potential who are pregnant or plan to become pregnant during the course of the study trial. Women of child-bearing potential (i.e., are not yet 3 years removed from their first menopausal symptom), who are not abstinent or exclusively in same sex relationships must
|
|
|
|
|
Test negative for pregnancy as indicated by a negative urine pregnancy test
|
|
|
|
|
Agree to use an approved contraception method for the entirety of the trial
|
|
|
|
|
Have a history or prior diagnosis of dementia or evidence of dementia at study screen
|
|
|
|
|
Have experienced a myocardial infarction, angina, or stroke within the past 12 months
|
|
|
|
|
Are receiving deep brain stimulation therapy
|
|
|
|
|
Are treated with a pump for continuous delivery of dopamine replacement medication
|
|
|
|
|
Use apomorphine rescue
|
|
|
|
|
Have received MRI guided high intensity focused ultrasound within the past 12 months
|
|
|
|
|
Experience frequent falls
|
|
|
|
|
Work night shifts
|
|
|
|
|
Use a hearing aid that is implanted or that cannot be easily removed and replaced
|
|
|
|
|
Have a cochlear implant
|
|
|
|
|
Have chronic (>3 months) tinnitus
|
|
|
|
|
Have previously been diagnosed with traumatic brain injury with ongoing sequalae
|
|
|
|
|
Have been diagnosed with a co-morbid neurological disorder that may present with symptoms overlapping with PD (e.g., stroke, brain tumor, epilepsy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, atypical Parkinsonism or aneurysm)
|
|
|
|
|
Have unresolved complications from a previous surgical procedure at the baseline visits, such as swelling or persistent pain, that requires medical intervention
|
|
|
|
|
Have active ear infections, or other significant ear problems
|
|
|
|
|
Have a recent history of frequent ear infections (≥ 1 per year over the past two years)
|
|
|
|
|
Are currently enrolled or have participated in another interventional clinical trial within the last 30 days
|
|
|
|
|
Have had eye surgery within the previous three months or ear surgery within the previous six months
|
|
|
|
|
Have planned surgery scheduled to occur during the study that requires sedation and/or would typically be followed with a prescription for pain management
|
|
|
|